A Drug for Heart Failure: The failure of the heart muscle to forcefully pump blood to the body’s tissues is a common disorder called Congestive heart failure. Heart attacks (stroke), high blood pressure, or diseases that weaken the heart muscle are common causes. The severe shortness of breath or fatigue that limits the ability to enjoy a life of the patients. Paradigm-HF is used in the large clinical trial, the new drug LCZ696 was used to treat heart failure, and it was highly effective. It achieved a substantial 20 % reduction in death or repeat hospitalization compared with the best currently available therapies. Currently, 20 % or more of patients hospitalized for heart failure are readmitted within 30 days which represents a significant burden for patients and the healthcare system.LCZ696 will probably be approved, providing a new, promising option for the 5.7 million Americans with heart failure.
Treatment for High Cholesterol: The PSCK9 inhibitor is second innovative drug therapy. These specify class of drugs has moved from discovery to the clinic more rapidly than any cardiovascular advancement. The single most important risk factor for developing coronary heart disease is an elevated level of cholesterol, LDL-C. The best drugs for reducing cholesterol, statins, have been shown to lower the risk of heart attack or stroke up to 35%. Statins have been available for 25 + years and have been enormously successful at reducing the burden of heart disease. Patients cannot tolerate statins or can’t take large enough dosages to adequately reduce cholesterol levels. LDL-C will be very high due to a genetic cause, and even the most powerful statins cannot reduce it to safe levels. PSCK9 inhibitors reduce bad LDL-C by as much as 50 % to 70 %. These drugs are given by every 2 weeks or once a month given by very small needles. These can be self-injected by the automated injector. This new class of drugs appears to be well tolerated even in patients who cannot take statins due to adverse effects.
Less Invasive Surgery: In 2011, the FDA approved a new procedure to treat heart valve disease without a major surgical operation, known as Trans-catheter aortic valve replacement (TAVR). This device is approved for who need an aortic valve replacement, but who are too high risk for standard open-heart surgery.